益肺清法对肺癌化疗疗效的远期预后的影响分析
|
摘要
目的探讨益肺清化法对肺癌化疗疗效的远期预后的影响。方法将78例非小细胞肺癌晚期患者按照随机数字表法分为对照组与观察组,各39例。对照组患者给予单纯化疗,观察组患者在对照组的基础上给予益肺清化颗粒治疗。所有患者均随访2年,比较2组患者近期临床疗效、生活质量、无进展生存期(PFS)、1年生存率、2年生存率。结果观察组患者PFS、中位生存时间及卡氏评分明显优于对照组(P <0. 05);但2组患者临床疗效、1年生存率与2年生存率比较,差异无统计学意义(P> 0. 05)。结论采用益肺清法辅助化疗治疗肺癌晚期患者可有效改善患者生活质量,延长患者生存期。
Objective To analyze the effect of Yifeiqinghua on the long-term prognosis of lung cancer with chemotherapy. Methods From January 2013 to December 2014,78 patients with advanced NSCLC who were diagnosed as non-small cell lung cancer in our hospital were selected as observation subjects and divided into control group and observation group according to random number table method,39 cases each. Patients in the control group received chemotherapy alone. Patients in the observation group were treated with Yifeiqinghua Granules on the basis of the control group. All patients were followed up for 2 years,The clinical efficacy,quality of life,progression-free survival( PFS),1-year survival and 2-year survival were compared between the two groups. Results The PFS,median survival time and Karnofsky scores in the observation group were significantly better than those in the control group( P < 0. 05) However,there was no significant difference in clinical efficacy,1-year survival rate and 2-year survival rate between the two groups( P > 0. 05). Conclusion The use of Yifeiqingfa adjuvant chemotherapy in patients with advanced lung cancer can effectively improve the quality of life of patients and prolong the survival of patients.
Objective To analyze the effect of Yifeiqinghua on the long-term prognosis of lung cancer with chemotherapy. Methods From January 2013 to December 2014,78 patients with advanced NSCLC who were diagnosed as non-small cell lung cancer in our hospital were selected as observation subjects and divided into control group and observation group according to random number table method,39 cases each. Patients in the control group received chemotherapy alone. Patients in the observation group were treated with Yifeiqinghua Granules on the basis of the control group. All patients were followed up for 2 years,The clinical efficacy,quality of life,progression-free survival( PFS),1-year survival and 2-year survival were compared between the two groups. Results The PFS,median survival time and Karnofsky scores in the observation group were significantly better than those in the control group( P < 0. 05) However,there was no significant difference in clinical efficacy,1-year survival rate and 2-year survival rate between the two groups( P > 0. 05). Conclusion The use of Yifeiqingfa adjuvant chemotherapy in patients with advanced lung cancer can effectively improve the quality of life of patients and prolong the survival of patients.
引文
[1]Shimada Y,Saji H,Kakihana M,et al.Survival outcomes for oligometastasis in resected non-small cell lung cancer[J].Asian Cardiovasc Thorac Ann,2015,23(8):44-937.
[2]Poullis M,Shackcloth M,Page R,et al.Metastatic index of non-small-cell lung cancer and long-term survival[J].Asian Cardiovasc Thorac Ann,2015,23(2):90-185.
[3]Kumarakulasinghe NB,van Zanwijk N,Soo RA.Molecular targeted therapy in the treatment of advanced stage nonsmall cell lung cancer(NSCLC)[J].Respirology,2015,20(3):8-370.
[4]董强,刘桂芹,刘建新,等.小细胞肺癌中医证候分布规律的临床研究[J].中医药导报,2014,20(11):30-32.
[5]Salemis NS,Nikou E,Liatsos C,et al.Small bowel perforation secondary to metastatic non-small cell lung cancer.Arare entity with a dismal prognosis[J].Gastrointest Cancer,2012,43(3):5-391.
[6]Pe1alver Cuesta JC,JordáAragón C,Manche1o Franch N,et al.Prognostic factors in non-small cell lung cancer less than 3 centimeters:actuarial analysis,accumulative incidence and risk groups[J].Arch Bronconeumol,2015,51(9):9-431.
[7]曹利平.肺癌放化疗后中医诊疗思路[J].现代中医药,2012,32(3):69-70.
[8]沈丽萍,刘苓霜,姜怡,等.中医综合方案维持治疗晚期非小细胞肺癌患者改善生活质量的临床疗效研究[J].中华中医药学刊,2014,32(7):1677-1681.
[9]李蓉,焦丽静,许玲.非小细胞肺癌的中医证型分布规律[J].上海中医药杂志,2012,46(9):95-97.
[10]孙小芸.中医益气健脾养血法对肺癌化疗患者骨髓抑制影响分析[J].内蒙古中医药,2015,34(11):47-47.
[11]李斐斐,崔一鸣.益肺清化颗粒治疗非小细胞肺癌研究进展[J].中华中医药杂志,2013,28(7):2067-2070.
[12]崔一呜,周斌,李斐斐,等.益肺清化颗粒对人肺癌PG细胞增殖、迁移与侵袭能力的影响[J].中华中医药杂志,2014,29(11):3592-3595.
[13]孙长侠.益肺清化颗粒联合NP化疗方案对非小细胞肺癌患者免疫功能的影响[J].实用心脑肺血管病杂志,2015,23(6):107-109.
[14]冯颖,宋卓.益肺清化法在肺癌防治中的应用及研究[J].中国中医基础医学杂志,2017,23(8):1099-1101.
[15]刘长春.益肺清化颗粒联合化疗用于中晚期非小细胞肺癌的临床观察[J].中国药房,2016,27(32):4536-4538.
[16]容国义,王淑美,唐末.中医化痰法治疗非小细胞肺癌疗效的Meta分析[J].中国临床药理学与治疗学,2017,22(7):787-794.
[2]Poullis M,Shackcloth M,Page R,et al.Metastatic index of non-small-cell lung cancer and long-term survival[J].Asian Cardiovasc Thorac Ann,2015,23(2):90-185.
[3]Kumarakulasinghe NB,van Zanwijk N,Soo RA.Molecular targeted therapy in the treatment of advanced stage nonsmall cell lung cancer(NSCLC)[J].Respirology,2015,20(3):8-370.
[4]董强,刘桂芹,刘建新,等.小细胞肺癌中医证候分布规律的临床研究[J].中医药导报,2014,20(11):30-32.
[5]Salemis NS,Nikou E,Liatsos C,et al.Small bowel perforation secondary to metastatic non-small cell lung cancer.Arare entity with a dismal prognosis[J].Gastrointest Cancer,2012,43(3):5-391.
[6]Pe1alver Cuesta JC,JordáAragón C,Manche1o Franch N,et al.Prognostic factors in non-small cell lung cancer less than 3 centimeters:actuarial analysis,accumulative incidence and risk groups[J].Arch Bronconeumol,2015,51(9):9-431.
[7]曹利平.肺癌放化疗后中医诊疗思路[J].现代中医药,2012,32(3):69-70.
[8]沈丽萍,刘苓霜,姜怡,等.中医综合方案维持治疗晚期非小细胞肺癌患者改善生活质量的临床疗效研究[J].中华中医药学刊,2014,32(7):1677-1681.
[9]李蓉,焦丽静,许玲.非小细胞肺癌的中医证型分布规律[J].上海中医药杂志,2012,46(9):95-97.
[10]孙小芸.中医益气健脾养血法对肺癌化疗患者骨髓抑制影响分析[J].内蒙古中医药,2015,34(11):47-47.
[11]李斐斐,崔一鸣.益肺清化颗粒治疗非小细胞肺癌研究进展[J].中华中医药杂志,2013,28(7):2067-2070.
[12]崔一呜,周斌,李斐斐,等.益肺清化颗粒对人肺癌PG细胞增殖、迁移与侵袭能力的影响[J].中华中医药杂志,2014,29(11):3592-3595.
[13]孙长侠.益肺清化颗粒联合NP化疗方案对非小细胞肺癌患者免疫功能的影响[J].实用心脑肺血管病杂志,2015,23(6):107-109.
[14]冯颖,宋卓.益肺清化法在肺癌防治中的应用及研究[J].中国中医基础医学杂志,2017,23(8):1099-1101.
[15]刘长春.益肺清化颗粒联合化疗用于中晚期非小细胞肺癌的临床观察[J].中国药房,2016,27(32):4536-4538.
[16]容国义,王淑美,唐末.中医化痰法治疗非小细胞肺癌疗效的Meta分析[J].中国临床药理学与治疗学,2017,22(7):787-794.